Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine received clearance from New Zealand’s Medsafe for its Clinical Trial Application of PM577a, targeting the H1069Q mutation in Wilson Disease. This authorization marks the first clinical trial clearance for an in vivo Prime Editing therapy from the company, enabling a global Phase 1/2 study to initiate in H2 2026.
Key figures
- Drug Name
- PM577a
- Phase Of Trial
- Phase 1/2
- Prevalence
- 1 in 30,000
- Data expected
- 2027
- Target mutation
- H1069Q
- Variant frequency
- 30-50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.